Skip to main content
. 2021 Jul 18;10(9):1071–1080. doi: 10.1002/psp4.12675

FIGURE 1.

FIGURE 1

Schematic of PBPK model development, validation, and application for predicting effects of hepatic impairment on the pharmacokinetics of OLZ/SAM. HI, hepatic impairment; OLZ/SAM, combination of olanzapine and samidorphan; PBPK, physiologically‐based pharmacokinetic; PK, pharmacokinetic